Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical application of a contingent screening strategy for trisomies with cell-free DNA: a pilot study

1 Aug 2019

Abstract excerpt

BACKGROUND: Different strategies have been designed for clinical implementation of cell-free DNA (cfDNA) testing. We aimed to evaluate the performance of a contingent strategy based on conventional screening and offering cfDNA to the intermediate-risk group, for the screening for trisomies 21, 18 and 13. Secondary objectives were to assess the uptake of cfDNA in women with intermediate-risk, to evaluate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Cancer Genomics and Diagnostics
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31370808
DOI: 10.1186/s12884-019-2434-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical application of a contingent screening strategy for trisomies with cell-free DNA: a pilot studyPMID 31370808Read ↗

Contingent first‐trimester screening for aneuploidies with cell‐free DNA in a Danish clinical settingSemantic proximity Read ↗

Clinical implementation of routine screening for fetal trisomies in the UK NHS : cell‐free DNA test contingent on results from first‐trimester combined testSemantic proximity Read ↗

<scp>UK NHS</scp> pilot study on cell‐free <scp>DNA</scp> testing in screening for fetal trisomies: factors affecting uptakeSemantic proximity Read ↗

Combined First Trimester Screening and Cell-Free Fetal DNA – “Next Generation Screening”Semantic proximity Read ↗

Screening for trisomies 21, 18 and 13 by cell‐free <scp>DNA</scp> analysis of maternal blood at 10–11 weeks' gestation and the combined test at 11–13 weeksSemantic proximity Read ↗

Cell-free DNA Analysis for Noninvasive Examination of TrisomySemantic proximity Read ↗

ISUOG updated consensus statement on the impact of cfDNA aneuploidy testing on screening policies and prenatal ultrasound practiceSemantic proximity Read ↗

Cell‐free <scp>DNA</scp> testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10–14 weeks and meta‐analysisSemantic proximity Read ↗

Clinical Perspective of Cell-Free DNA Testing for Fetal AneuploidiesSemantic proximity Read ↗

First‐trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell‐free DNA testingSemantic proximity Read ↗

Cell-free DNA Analysis for Noninvasive Examination of TrisomySemantic proximity Read ↗

Current controversies in prenatal diagnosis 2: Cell‐free DNA prenatal screening should be used to identify all chromosome abnormalitiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.